Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.38 |
| ▸ | HTR6 | P50406 | 9/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL5814494 | 0.91 | KDM4E (0.37) | KDM4ETSHRCYP1A1HTR6 | |
| SCHEMBL5803128 | 0.82 | HRH4 (0.41) | TSHRHTR6 | |
| SCHEMBL5804780 | 0.82 | DRD2 (0.41) | HTR6 | |
| SCHEMBL5824219 | 0.81 | HTR2C (0.44) | CYP1A1HTR6 | |
| SCHEMBL5805891 | 0.81 | HTR2C (0.44) | CYP1A1HTR6 | |
| SCHEMBL5806198 | 0.81 | HTR2C (0.44) | CYP1A1HTR6 | |
| SCHEMBL5803281 | 0.77 | LMNA (0.39) | TSHRCYP1A1L3MBTL1 | |
| Trifluoroacetic Acid SCHEMBL5824147 | 0.76 | CDK2 (0.38) | TSHRHTR6GSK3BL3MBTL1 | |
| Trifluoroacetic Acid SCHEMBL5818377 | 0.76 | HTR1A (0.38) | KDM4ETSHRHTR6 | |
| Trifluoroacetic Acid SCHEMBL5955920 | 0.75 | HTR2C (0.44) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060142269-A1 | New compounds | BIOVITRUM AB (SE) | 2006-06-29 | — | — | US | claimed |
| WO-2006062481-A1 | NEW BENZOFURAN DERIVATIVES AND THEIR USE IN THE TREATMENT OF OBESITY, TYPE II DIABETES AND CNS DISORDERS . | BIOVITRUM AB (SE) | 2006-06-15 | — | — | WO | claimed |
| US-20060142269-A1 | New compounds | BIOVITRUM AB (SE) | 2006-06-29 | — | — | US | disclosed |
| WO-2006062481-A1 | NEW BENZOFURAN DERIVATIVES AND THEIR USE IN THE TREATMENT OF OBESITY, TYPE II DIABETES AND CNS DISORDERS . | BIOVITRUM AB (SE) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142269-A1 | New compounds | GPR119, GLP1R, IAPP | KDM4E 3934/4885TSHR 572/4885CYP1A1 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.